ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer
May 4, 2021 2:00 pmRAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more